XML 38 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Additional Information (Detail) (USD $)
9 Months Ended 12 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Sep. 30, 2012
Sep. 30, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Shares reserve for issuance 6,055,535      
Options granted and outstanding to purchase 2,859,794   1,910,794 729,096
Options granted outside of Equity Incentive plans 251,200      
Options granted 949,000   1,229,500  
Stock-based compensation expense $ 1,114,375 $ 837,188    
Fair value of the options granted 1,197,588 3,505,912    
Intrinsic value of the options exercised 0      
Stock options exercised 0   4,883  
Dividend yield 0.00%       
Calando Pharmaceuticals, Inc.
       
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Fair value of the options granted 0 33,690    
Pre-tax compensation expense 39,169      
Weighted average period to recognize pre-tax compensation expense 2 years 2 months 12 days      
Arrowhead
       
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Pre-tax compensation expense $ 3,775,514      
Weighted average period to recognize pre-tax compensation expense 2 years 10 months 24 days      
2000 Stock Option Plan
       
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Shares reserve for issuance 153,200      
Options granted and outstanding to purchase 152,900      
2004 Equity Incentive Plan
       
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Shares reserve for issuance 2,965,860      
Options granted and outstanding to purchase 2,455,694      
Shares authorized for issuance 3,000,000      
Shares available for issuance 510,166      
Options granted 949,000